Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Sales and Divestitures (2016 - 2025)

Ptc Therapeutics (PTCT) has 9 years of Gains from Sales and Divestitures data on record, last reported at $90625.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 90.59% year-over-year to $90625.0; the TTM value through Dec 2025 reached $90625.0, down 90.59%, while the annual FY2025 figure was $90625.0, 90.59% down from the prior year.
  • Gains from Sales and Divestitures reached $90625.0 in Q4 2025 per PTCT's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.2 million in Q3 2025 and bottomed at $90625.0 in Q4 2025.
  • Average Gains from Sales and Divestitures over 5 years is $673204.4, with a median of $726257.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 82.33% in 2023, then plummeted 90.59% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $335114.0 in 2021, then skyrocketed by 50.65% to $504851.0 in 2022, then surged by 82.33% to $920488.0 in 2023, then grew by 4.68% to $963543.0 in 2024, then tumbled by 90.59% to $90625.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $90625.0 in Q4 2025, $1.2 million in Q3 2025, and $1.1 million in Q2 2025.